Biotech · Public company · Rockville, MD, US
REGENXBIO Inc.
Ticker RGNX · SEC CIK 0001590877
Track this companyFree. Adds REGENXBIO Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2314 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- RGX-121Phase 3 · Mucopolysaccharidosis Type II (MPS II)ClinicalTrials.gov · fetched Nov 12, 2026
- RGX-121-3102Phase 3 · MPS IIClinicalTrials.gov · fetched Nov 12, 2026
- RGX-202Phase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- AAV directed hLDLR gene therapyPhase 2 · Homozygous Familial Hypercholesterolemia (HoFH)ClinicalTrials.gov · fetched Nov 12, 2026
- RGX-111Phase 2 · Mucopolysaccharidosis Type I (MPS I)ClinicalTrials.gov · fetched Nov 12, 2026
- RGX-314Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AAV8 DetectCDxDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- Long-term Follow-UpMucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionMucopolysaccharidosis IClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionDuchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- ObservationalMucopolysaccharidosis IIClinicalTrials.gov · fetched Nov 12, 2026
- RGX-202ClinicalTrials.gov · fetched Nov 12, 2026
- Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene TherapyHomozygous Familial Hypercholesterolemia (HoFH)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials23
- RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 25, 2025ClinicalTrials.gov NCT07236606 · fetched Nov 12, 2026
- Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)PHASE2 · RECRUITING · started Mar 18, 2025ClinicalTrials.gov NCT06942520 · fetched Nov 12, 2026
- Long Term Follow-up for RGX-202ENROLLING_BY_INVITATION · started May 8, 2024ClinicalTrials.gov NCT06491927 · fetched Nov 12, 2026
- Long Term Follow-Up for RGX-111ENROLLING_BY_INVITATION · started Jul 24, 2023ClinicalTrials.gov NCT06103487 · fetched Nov 12, 2026
- AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 4, 2023ClinicalTrials.gov NCT05693142 · fetched Nov 12, 2026
- AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMDACTIVE_NOT_RECRUITING · started Dec 20, 2022ClinicalTrials.gov NCT05683379 · fetched Nov 12, 2026
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 4, 2022ClinicalTrials.gov NCT05296447 · fetched Nov 12, 2026
- Mucopolysaccharidosis Type II ObservationalWITHDRAWN · started Mar 1, 2022ClinicalTrials.gov NCT04591834 · fetched Nov 12, 2026
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 13, 2022ClinicalTrials.gov NCT05407636 · fetched Nov 12, 2026
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDPHASE2 · ENROLLING_BY_INVITATION · started Dec 20, 2021ClinicalTrials.gov NCT05210803 · fetched Nov 12, 2026
- Long-term Follow-Up for RGX-121ACTIVE_NOT_RECRUITING · started Mar 14, 2021ClinicalTrials.gov NCT04597385 · fetched Nov 12, 2026
- RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)PHASE1_PHASE2 · COMPLETED · started Mar 11, 2021ClinicalTrials.gov NCT04571970 · fetched Nov 12, 2026
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDPHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 29, 2020ClinicalTrials.gov NCT04704921 · fetched Nov 12, 2026
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 20, 2020ClinicalTrials.gov NCT04567550 · fetched Nov 12, 2026
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 25, 2020ClinicalTrials.gov NCT04514653 · fetched Nov 12, 2026
- Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) PatientsCOMPLETED · started Dec 4, 2019ClinicalTrials.gov NCT04148001 · fetched Nov 12, 2026
- A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501UNKNOWN · started Sep 30, 2019ClinicalTrials.gov NCT04080050 · fetched Nov 12, 2026
- RGX-111 Gene Therapy in Patients With MPS IPHASE1_PHASE2 · SUSPENDED · started Apr 3, 2019ClinicalTrials.gov NCT03580083 · fetched Nov 12, 2026
- CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 27, 2018ClinicalTrials.gov NCT03566043 · fetched Nov 12, 2026
- Mucopolysaccharidosis Type II Natural HistoryCOMPLETED · started Sep 27, 2017ClinicalTrials.gov NCT03529786 · fetched Nov 12, 2026
- Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD TrialPHASE1_PHASE2 · COMPLETED · started Mar 29, 2017ClinicalTrials.gov NCT03066258 · fetched Nov 12, 2026
- A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)PHASE1_PHASE2 · TERMINATED · started Mar 1, 2016ClinicalTrials.gov NCT02651675 · fetched Nov 12, 2026
- Expanded Access to RGX-202TEMPORARILY_NOT_AVAILABLEClinicalTrials.gov NCT07652606 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 24, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026